Home
Interesting shortcuts
EFFRA Members' Perspectives
News Dashboard
Projects
Projects
Results, demos etc.
Results, demos etc.
Structured Wiki
Search
FoF and Made in Europe Partnership
Demonstrators, pilots, prototypes
Exploitable result(s)
Significant innovations and lessons learned, training aspects
Report - Video - Presentation - Publication....?
Project clusters
Company perspectives
Manufacturing future products
Manufacturing performance characteristics
Technologies and enablers
ICT performance characteristics
Standards and standardisation
Contribution of R&I projects to standardisation
Regulatory and policy aspects
Standards - other classifications
Business model aspects
Pathways
MiE SRIA R&I Priorities
Public Consultation - MiE 25-27 Priorities (input is publicly available)
MiE KPIs
Relevant open calls
EU-Programme-Call
NACE code
EFFRA WG pointers
Pathways
Pathways
Project ideas
Project ideas
People & organisations
People
Organisations
portal@effra.eu
Visit the EFFRA website
Login
Projects
COLLABS
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
COLLABS
mapped on
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2014-01-two-stage
IMI2-2014-01-01 Translational approaches to disease modifying therapy of Type 1 Diabetes Mellitus (T1DM)
H2020-JTI-IMI2-2014-02-single-stage
IMI2-2014-02-01 Vaccine development Phase I, II, and III
IMI2-2014-02-04 Deployment and compliance of vaccination regimens
IMI2-2014-02-05 Rapid diagnostic tests
H2020-JTI-IMI2-2015-03-two-stage
IMI2-2015-03-01 Remote Assessment of Disease and Relapse - CNS
IMI2-2015-03-02 Assessing Risk and Progression of Prediabetes and Type 2 Diabetes to Enable Disease Modification
IMI2-2015-03-03 Linking Clinical Neuropsychiatry and Quantitative Neurobiology
IMI2-2015-03-05 Pertussis vaccination research
H2020-JTI-IMI2-2015-05-two-stage
IMI2-2015-05-01 Patient perspective elicitation on benefits and risks of medicinal products, from development through the entire life cycle, to inform the decision-making process by regulators and Health Technology Assessment bodie
IMI2-2015-05-02 Diabetic Kidney Disease Biomarkers (DKD-BM)
IMI2-2015-05-03 Inflammation and AD: modulating microglia function – focussing on TREM2 and CD33
IMI2-2015-05-04 Understanding the role of amyloid imaging biomarkers in the current and future diagnosis and management of patients across the spectrum of cognitive impairment (from pre-dementia to dementia)
IMI2-2015-05-05 Evolving models of patient engagement and access for earlier identification of Alzheimer’s disease: Phased expansion study
IMI2-2015-05-06 From ApoE biology to validated Alzheimer’s disease targets
H2020-JTI-IMI2-2015-06-two-stage
IMI2-2015-06-01 Development of Quantitative System Toxicology (QST) approaches to improve the understanding of the safety of new medicines
IMI2-2015-06-02 Establishing impact of RSV infection, resultant disease and public health approach to reducing the consequences
IMI2-2015-06-03 Real World Outcomes Across the AD Spectrum (ROADS) to Better Care
IMI2-2015-06-04 Development of an outcomes-focused data platform to empower policy makers and clinicians to optimize care for patients with hematologic malignancies
H2020-JTI-IMI2-2015-07-two-stage
IMI2-2015-07-01 VALIDATION OF TRANSLATIONAL IMAGING METHODS IN DRUG SAFETY ASSESSMENT (TRISTAN)
IMI2-2015-07-02 IDENTIFICATION OF DRUGGABLE TARGETS MODULATING MISFOLDED PROTEINS IN ALZHEIMER’S AND PARKINSON’S DISEASES
IMI2-2015-07-03 PATHOLOGICAL NEURON-GLIA INTERACTIONS IN NEUROPATHIC PAIN
IMI2-2015-07-04 DRY AGE-RELATED MACULAR DEGENERATION: DEVELOPMENT OF NOVEL CLINICAL ENDPOINTS FOR CLINICAL TRIALS WITH A REGULATORY AND PATIENT ACCESS INTENTION
IMI2-2015-07-05 A COMPREHENSIVE ‘PAEDIATRIC PRECLINICAL POC PLATFORM’ TO ENABLE CLINICAL MOLECULE DEVELOPMENT FOR CHILDREN WITH CANCER
IMI2-2015-07-06 COORDINATION AND SUPPORT ACTIONS (CSA) FOR THE BIG DATA FOR BETTER OUTCOMES PROGRAMME
IMI2-2015-07-07 INCREASE ACCESS AND USE OF HIGH QUALITY DATA TO IMPROVE CLINICAL OUTCOMES IN HEART FAILURE (HF), ATRIAL FIBRILLATION (AF), AND ACUTE CORONARY SYNDROME (ACS) PATIENTS
H2020-JTI-IMI2-2015-08-single-stage
IMI2-2015-08-01 Ebola and other filoviral haemorrhagic fevers (Ebola+) programme: future outbreaks
H2020-JTI-IMI2-2016-09-two-stage
IMI2-2016-09-01 ADDRESSING THE CLINICAL BURDEN OF CLOSTRIDIUM DIFFICILE INFECTION (CDI): EVALUATION OF THE BURDEN, CURRENT PRACTICES AND SET-UP OF A EUROPEAN RESEARCH PLATFORM (PART OF THE IMI NEW DRUGS FOR BAD BUGS (ND4BB) PROGRAMME)
IMI2-2016-09-02 DEVELOPMENT OF IMMUNE TOLERANCE THERAPIES FOR THE TREATMENT OF RHEUMATIC DISEASES
IMI2-2016-09-03 DATA QUALITY IN PRECLINICAL RESEARCH AND DEVELOPMENT
IMI2-2016-09-04 NEXT GENERATION OF ELECTRONIC TRANSLATIONAL SAFETY – NEXGETS
IMI2-2016-09-05 IDENTIFICATION AND VALIDATION OF BIOMARKERS FOR NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND ACROSS THE SPECTRUM OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
IMI2-2016-09-06 JOINT INFLUENZA VACCINE EFFECTIVENESS STUDIES
H2020-JTI-IMI2-2016-10-two-stage
IMI2-2016-10-01 Understanding hypoglycaemia: the underlying mechanisms and addressing clinical determinants as well as consequences for people with diabetes by combining databases from clinical trials
IMI2-2016-10-02 How Big Data could support better diagnosis and treatment outcomes for Prostate Cancer
IMI2-2016-10-03 Improving the care of patients suffering from acute or chronic pain
IMI2-2016-10-04 Creation of a pan-European Paediatric Clinical Trials Network
IMI2-2016-10-05 Biomanufacturing 2020: Development of Innovative high throughput analytical tools and methods to characterize cell culture fluid during development and commercial cell culture processes
IMI2-2016-10-06 Unlocking the Solute Carrier Gene-Family for Effective New Therapies (Unlock SLCs)
IMI2-2016-10-07 Patient perspectives in medicines lifecycle
IMI2-2016-10-08 Personalised medicine approaches in autism spectrum disorders
H2020-JTI-IMI2-2017-11-single-stage
IMI2-2017-11-01 Exploitation of IMI project results
H2020-JTI-IMI2-2017-12-two-stage
IMI2-2017-12-01 Development and validation of technology enabled, quantitative and sensitive measures of functional decline in people with early stage Alzheimer’s Disease (RADAR-AD)
IMI2-2017-12-02 FAIRification of IMI and EFPIA data
IMI2-2017-12-03 Development of sensitive and validated clinical endpoints in primary Sjögren’s Syndrome (pSS)
IMI2-2017-12-04 European Health Data Network (EHDN)
IMI2-2017-12-05 Analysing the infectious disease burden and the use of vaccines to improve healthy years in aging populations
IMI2-2017-12-06 Discovery and characterisation of blood-brain barrier targets and transport mechanisms for brain delivery of therapeutics to treat neurodegenerative & metabolic diseases
IMI2-2017-12-07 European Screening Centre: unique library for attractive biology (ESCulab)
H2020-JTI-IMI2-2017-13-two-stage
IMI2-2017-13-01 Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches
IMI2-2017-13-02 Genome-Environment Interactions in Inflammatory Skin Disease
IMI2-2017-13-03 The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
IMI2-2017-13-04 Mitochondrial Dysfunction in Neurodegeneration
IMI2-2017-13-05 Support and coordination action for the projects of the Neurodegeneration area of the Innovative Medicines Initiative
IMI2-2017-13-06 A sustainable European induced pluripotent stem cell platform
IMI2-2017-13-07 Linking digital assessment of mobility to clinical endpoints to support regulatory acceptance and clinical practice
IMI2-2017-13-08 Human Tumour Microenvironment Immunoprofiling
IMI2-2017-13-09 ConcePTION – Continuum of Evidence from Pregnancy Exposures, Reproductive Toxicology and Breastfeeding to Improve Outcomes Now
IMI2-2017-13-10 Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system
IMI2-2017-13-11 Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease
IMI2-2017-13-14 Pilot programme on a Clinical Compound Bank for Repurposing: Neurodegenerative diseases
IMI2-2017-13-15 Pilot programme on a Clinical Compound Bank for Repurposing: Rare/orphan diseases
H2020-JTI-IMI2-2018-14-two-stage
IMI2-2018-14-01 Targeted immune intervention for the management of non-response and relapse
IMI2-2018-14-02 Non-invasive clinical molecular imaging of immune cells
IMI2-2018-14-03 Development of a platform for federated and privacy-preserving machine learning in support of drug discovery
IMI2-2018-14-04 Centre Of Excellence – Remote Decentralised Clinical Trials
H2020-JTI-IMI2-2018-15-two-stage
IMI2-2018-15-01 Integrated research platforms enabling patient-centric drug development
IMI2-2018-15-02 Blockchain Enabled Healthcare
IMI2-2018-15-03 Microenvironment imposed signatures in tissue and liquid biopsies in immune- mediated diseases
IMI2-2018-15-04 Emerging translational safety technologies and tools for interrogating human immuno-biology
IMI2-2018-15-06 Digital endpoints in neurodegenerative and immune-mediated diseases
IMI2-2018-15-07 AMR Accelerator programme Pillar A: Capability Building Network to accelerate and validate scientific discoveries
IMI2-2018-15-08 AMR Accelerator programme Pillar B: Tuberculosis drug development network to accelerate and validate scientific discoveries and advance the R&D pipeline of new and innovative agents to address the global tuberculosis epidemic
H2020-JTI-IMI2-2018-16-single-stage
IMI2-2018-16-01 Progress new assets (one pre-new molecular entity (preNME) and one first-time-in-human (FTIH) start) for TB that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors
IMI2-2018-16-02 Progress novel assets (one FTIH start) for non-tubercular mycobacteria (NTM) that may act synergistically with bedaquiline and cytochrome bc drugs
IMI2-2018-16-04 Determination of gepotidacin levels in tonsils and prostatic tissue
IMI2-2018-16-06 Functional Ethionamide boosters: a novel combination for tuberculosis therapy
IMI2-2018-16-07 Intravenous treatments of serious infections (urinary tract infections, intra-abdominal infections & hospital-acquired pneumonia/ventilator associated pneumonia) caused by Gram(-) bacteria (Enterobacteriaceae +/- Pseudomonas and/or Acinetobacter)
H2020-JTI-IMI2-2019-17-two-stage
IMI2-2019-17-01 Optimising future obesity treatment
IMI2-2019-17-02 Open access chemogenomics library and chemical probes for the druggable genome
IMI2-2019-17-03 Intelligent prediction and identification of environmental risks posed by human medicinal products
H2020-JTI-IMI2-2019-18-two-stage
IMI2-2019-18-01 Central repository of digital pathology slides to support the development of artificial intelligence tools
IMI2-2019-18-02 Health Outcomes Observatories – empower patients with tools to measure their outcomes in a standardised manner creating transparency of health outcomes
IMI2-2019-18-03 Improving patient access, understanding and adherence to healthcare information: an integrated digital health information project
IMI2-2019-18-04 Establishing international standards in the analysis of patient reported outcomes and health-related quality of life data in cancer clinical trials
IMI2-2019-18-05 Accelerating research & innovation for advanced therapy medicinal products
IMI2-2019-18-06 Supporting the development of engineered T cells
H2020-JTI-IMI2-2019-19-single-stage
IMI2-2019-19-01 Restricted Call to maximise impact of IMI2 JU objectives and scientific priorities
H2020-JTI-IMI2-2020-21-single-stage
IMI2-2020-21-01